Parabilis MedicinesPBLS
Recorded

Parabilis Medicines Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Mathai MammenChairman, CEO and President

All right. Good afternoon again. I am so pleased to be able to present on behalf of Parabilis. The last year has been quite the inflection point for us, last 12, 15 months. I will take you through some of the current data, the strategy, our plans for value creation, and tell you what to expect in the next year. As always, I will be making some forward-looking statements here. Please read our SEC documents for the risks in our business. This is a snapshot of where we are as Parabilis. I will tell you more about these as we go. At a high level, we reported some fabulous data recently at the ESMO meeting on our lead program, desmoid tumors, with a drug that we call zolucatetide. We observed in that tumor type a 72% ORR at 32 weeks.

Mathai MammenChairman, CEO and President

We have met with the FDA at an end-of-phase II meeting and have a clear green light to proceed with phase III that we call the PEDESTAL study, and that is slated to start in the first half of next year, as soon as we can get it up and going. We will talk here about some of the large expansion opportunities in FAP and ACP, a craniopharyngioma that is a particularly exciting disease for us. You will see a lot more in the year to come on hepatocellular carcinoma. We just started a collaboration with Revolution Medicines in colorectal cancer and MSS CRC. I will show you some data for the first time in other indications that we are getting extremely excited by for zolucatetide that we hope to tie together in a basket study.

Mathai MammenChairman, CEO and President

We continue to make really strong progress on the rest of our pipeline in ERG degraders for prostate cancer, ARON allosteric degraders for prostate cancer, and other programs that I will tell you about in a moment. As I said, we signed a great collaboration with Regeneron that is underway right now, and we hope to begin recruiting into that study. We signed a few months ago a really major collaboration with Regeneron that I will tell you about, but it really is a vote of confidence in our platform, where we are exploring five different programs with Regeneron outside of oncology. We have a strong balance sheet. We ended the quarter with a little over $1 billion. We had a particularly successful IPO the middle of this year, and we had done a private financing before that as well.

Mathai MammenChairman, CEO and President

Our strategy has four pillars, and we will take you through all of it here today. First, and perhaps most importantly, we need to deliver on zolucatetide key anchor indications. These include desmoid, FAP, and ACP, and I will go into these in a bit more depth. For now, I want to emphasize that these are all driven by β-catenin or APC mutations uniformly. As such, we expect relatively uniform activity in these disease states. There is no patient selection in these, and they all require a lifetime of care. We believe that success in these three indications can create a very large product opportunity for us, and as far as we know right now, we remain the only β-catenin TCF inhibitor, and we have been in the clinic for about three and a half years, and we remain alone.

Mathai MammenChairman, CEO and President

Second, we want to expand on our β-catenin franchise. There are a host of other Wnt β-catenin-driven cancers and indications for us. Coming soon is hepatocellular carcinoma. We will release some data in the first quarter of next year. We have a whole tumor agnostic pathway planned as well. I told you about RevMed's collaboration with zoldonrasib and cetuximab with zolucatetide in MSS CRC, and we have some really great work happening right now in the next generation of β-catenin modulators. These are β-catenin degraders, and we plan on bringing at least one, if not two or more, of these as we see particular insights in β-catenin biology that I do not think anyone knows about right now because of the tools that we have available to us. Beyond that, the third component here is to advance our pipeline.

Mathai MammenChairman, CEO and President

We are very excited about our two prostate cancer programs, an ERG degrader and ARON degrader. I will describe both of these in a moment. We are working on other very compelling targets that I am convinced will be very meaningful contributors to medicine. One of them is a cyclin D1 degrader, a long sought-after target. We also have a very interesting program brewing in p53 RIPTAC, and these are intended to kill cells that bear particular p53 mutations. There are other targets as well that we are pursuing. Everything in our portfolio we feel is unique. They are not meant to be extensions or incremental innovations over other work. Then finally, we are constantly expanding our modality.

Mathai MammenChairman, CEO and President

We have grown expert at making Helicon peptides that can engage targets that others cannot, and we can make different flavors of these that are either direct inhibitors of a protein-protein interaction, a degrader, or a RIPTAC equivalent that we call a HIPTAC. Regeneron allows us to explore foundationally delivering these targets via antibody if we wish to. This is a snapshot of the pipeline. I will not repeat this. These are the same programs, but you see here that zolucatetide is in the lead, and the other programs, we intend to file INDs on both prostate programs in 2027 next year. As a reminder, our core platform is presented on this slide. On the left is the problem statement that most proteins inside cells simply lack drug-binding pockets.

Mathai MammenChairman, CEO and President

They do not have sufficient depth in these pockets to engage a small molecule, and as such, they are not on the table in any pharma, any biotech company. β-catenin is an example of that has been tried by every major pharma that is interested in oncology, which is most of them, including myself when I was at Merck and J&J, but everyone has come up empty. That is a physics problem. It is not a how you do it problem, but it is a physics problem. You just cannot. The pocket does not exist. So what we have done is create these peptides that act like antibodies in that they have large surface area and can cover pocket-less proteins, low curvature surfaces on proteins that stitch together a lot of low-energy interactions to make a very potent compound.

Mathai MammenChairman, CEO and President

Just like an antibody does for extracellular targets, we do, and in a way, we are like intracellular antibodies. That modality, I would say, is fully reduced to practice right now. It has been incubated within our company, first FogPharma, now Parabilis Medicines, for about a decade, and prior to that was created in the labs of Greg Verdine over probably the prior 15 years. Let me talk now a little bit more about zolucatetide. Zolucatetide targets the interaction between β-catenin and TCF. That is the key node in the Wnt pathway and is the node that everyone has been after for a very long time. Other aspects of the pathway are much less useful to drug. This is the node that shines in, like for example, the Broad's DepMap and every piece of biology that has been revealed about the pathway.

Mathai MammenChairman, CEO and President

We have chosen to start with desmoid, FAP, and adamantinomatous craniopharyngioma, as they are pure tumors in that they are 100% driven by either APC or β-catenin, and there is no patient selection needed. Our expectation is, since they are very simple tumors, they do not have other mutations, that we would see a uniformity of activity, and that is the direction that we are seeing today. Other tumors include hepatocellular carcinoma. I will explain this more, but a good percentage of these are driven by β-catenin. Colorectal cancer is almost entirely APC as a truncal mutation, and then there are additional Wnt β-catenin-driven indications that are either β-catenin or APC. The selection here is for anyone that really has a β-catenin or APC mutation, which happens to be about 10% of all cancers. Let us begin with desmoid tumors. Desmoid tumors, there are about 30,000 patients in the U.S. and proportionally more globally.

Mathai MammenChairman, CEO and President

11,000 of these U.S.-based patients are actively managed today. They seek physician care because they have acute distress. They have pain or some major dysfunction, sometimes in a limb. Sometimes we have seen patients with tumors in their throat and they cannot breathe. They come in to their physicians in a lot of distress. Today, only a couple thousand of those patients we expect to be treated with a gamma-secretase inhibitor, now approved. OGSIVEO, nirogacestat, is approved for treating desmoid tumors. I will explain why it is such a small portion as we go, but it is largely the side effect profile. We think that there is a lot of unmet need. We get to know the patients in this field, and we will talk more about a couple of them as archetypes, but you will see that there is so much unmet need in this space that is not being adequately treated.

Mathai MammenChairman, CEO and President

Really what we are looking for are much greater reliable response rates. We are looking for improved safety and tolerability profile, and we are looking for quick response. These are the data that we presented at ESMO. We reported a 32-week landmark analysis showing 72% ORR and disease control in 100% of patients, so no disease progressions, no treatment-related AE-related or no AE-related discontinuations. Only two of the 76 patients discontinued. One was for a CR, and they felt completely better, and the other one was for certain logistical reasons, well-tolerated drug in that person with a DPR. That is a really good status of this trial at the moment. As I mentioned, we have chosen our dose and our endpoint, and we are on track for phase III. Our top-line data are anticipated in 2029 from this phase III study.

Mathai MammenChairman, CEO and President

This is a comparison, a cross-trial comparison with all the caveats of cross-trial comparisons. With that caveat, we try to do our best in doing an apples-to-apples comparison of these studies. Nirogacestat and nirogacestat are both gamma-secretase inhibitors, and you see there a 24-week landmark analysis that we report about 62%, relative to 20s, in the 21, 25% for the gamma-secretase inhibitors. At 32 to 36 weeks, at 32 weeks, ours is 72%, and at 36 weeks, the others are 35%-40%. Significantly better activity. If you look at the reported end of a couple year, 88 to 90 weeks, the two gamma-secretase inhibitors settled out at about 40%-55% ORR. We feel really good about these data, and we feel that these are consistent data from the smaller datasets reported earlier.

Mathai MammenChairman, CEO and President

Safety also, now that we've gone from about 200 patient months to over 450 patient months in the last six months in our latest data cut, and we see a completely consistent safety and tolerability. Our plan here continues to be, and this is what we will do in phase III, an induction maintenance regimen. What that means is we will begin with 450 milligrams for four months, and the reason for that is that these patients are in acute distress and they want rapid reduction. That's a more aggressive dose, and the most common AEs reported at that dose are fatigue, nausea, and alopecia.

Mathai MammenChairman, CEO and President

At the maintenance dose of 150 milligrams weekly, which we will deliver in phase III as 300 milligrams every other week, you see that the tolerability and safety profile is a lot better, and the patients reduce to that after four months, and they're out of their acute distress, and that's the dose they remain on indefinitely, potentially for many years. You see there that they're not bothered by. Really, like a reminder, no AE-based discontinuations in our trial. Patients have been on up to 2.7 years, and many over a year at this point, or well over a year. We feel overall that this is a well-tolerated drug in the maintenance phase, and patients seem to really appreciate the efficacy and the safety tolerability. Notably, there's no association with ovarian toxicity.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day